{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:22:00Z","timestamp":1760188920760},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,10,24]],"date-time":"2007-10-24T00:00:00Z","timestamp":1193184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"},{"start":{"date-parts":[[2007,10,24]],"date-time":"2007-10-24T00:00:00Z","timestamp":1193184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1007\/s00296-007-0471-x","type":"journal-article","created":{"date-parts":[[2007,10,23]],"date-time":"2007-10-23T11:20:55Z","timestamp":1193138455000},"page":"205-215","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["The potential utility of B cell-directed biologic therapy in autoimmune diseases"],"prefix":"10.1007","volume":"28","author":[{"given":"D. G.","family":"Arkfeld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,10,24]]},"reference":[{"key":"471_CR1","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/ard.2005.047621","volume":"65","author":"K Ahmadi-Simab","year":"2006","unstructured":"Ahmadi-Simab K, Lamprecht P, Jankowiak C, Gross WL (2006) Successful treatment of refractory adult onset Still\u2019s disease with rituximab. Ann Rheum Dis 65:1117\u20131118","journal-title":"Ann Rheum Dis"},{"key":"471_CR2","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1136\/ard.2004.027128","volume":"64","author":"K Ahmadi-Simab","year":"2005","unstructured":"Ahmadi-Simab K, Lamprecht P, Nolle B, Ai M, Gross WL (2005) Successful treatment of refractory anterior scleritis in primary Sjogren\u2019s syndrome with rituximab. Ann Rheum Dis 64:1087\u20131088","journal-title":"Ann Rheum Dis"},{"key":"471_CR3","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/ajh.20166","volume":"77","author":"A Ahmed","year":"2004","unstructured":"Ahmed A, Aggarwal A, Sharma D, Dave HP, Kinsella V, Rick ME et al (2004) Rituximab for treatment of refractory\/relapsing thrombotic thrombocytopenic purpura (TTP). Am J Hematol 77:171\u2013176","journal-title":"Am J Hematol"},{"key":"471_CR4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00277-006-0226-x","volume":"86","author":"PR Ames","year":"2007","unstructured":"Ames PR, Tommasino C, Fossati G, Scenna G, Brancaccio V, Ferrara F (2007) Limited effect of rituximab on thrombocytopaenia and anticardiolipin antibodies in a patient with primary antiphospholipid syndrome. Ann Hematol 86:227\u2013228","journal-title":"Ann Hematol"},{"key":"471_CR5","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/j.1445-5994.2006.01113.x","volume":"36","author":"A Anandacoomarasamy","year":"2006","unstructured":"Anandacoomarasamy A, Gibson J, McGill N (2006) \u2018Cure\u2019 of life-threatening antiphospholipid syndrome with rituximab. Intern Med J 36:474\u2013475","journal-title":"Intern Med J"},{"key":"471_CR6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/art.10764","volume":"48","author":"JH Anolik","year":"2003","unstructured":"Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J et al (2003) The relationship of Fc\u03b3RIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48:455\u2013459","journal-title":"Arthritis Rheum"},{"issue":"Suppl. II","key":"471_CR7","first-page":"199","volume":"66","author":"P Aranda-Pereira","year":"2007","unstructured":"Aranda-Pereira P, Melendez-Mercado C, Jaimes-Hernandez J (2007) Rituximab, alternative treatment in refractory idiopathic inflammatory myopathies. Ann Rheum Dis 66(Suppl. II):199 [Abstract No. THU0236]","journal-title":"Ann Rheum Dis"},{"key":"471_CR8","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1136\/ard.2005.044420","volume":"65","author":"PM Aries","year":"2006","unstructured":"Aries PM, Hellmich B, Voswinkel J, Both M, Nolle B, Holl-Ulrich K et al (2006) Lack of efficacy of rituximab in Wegener\u2019s granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 65:853\u2013858","journal-title":"Ann Rheum Dis"},{"key":"471_CR9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","volume":"146","author":"DM Arnold","year":"2007","unstructured":"Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C et al (2007) Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 146:25\u201333","journal-title":"Ann Intern Med"},{"key":"#cr-split#-471_CR10.1","unstructured":"Bar-Or A, Calabresi P, Arnold D, Markowitz C, Shafer S, Kasper L et al (2007) A Phase I, open-label, multicenter study to evaluate the safety and activity of rituximab in adults with relapsing-remitting multiple sclerosis (RRMS). In: American Academy of Neurology 59th Annual Meeting"},{"key":"#cr-split#-471_CR10.2","unstructured":"Boston, April 28-May 5, 2007 [Abstract No. S.02.001]"},{"key":"471_CR11","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1182\/blood-2003-10-3597","volume":"103","author":"S Berentsen","year":"2004","unstructured":"Berentsen S, Ulvestad E, Gjertsen BT, Hjorth-Hansen H, Langholm R, Knutsen H et al (2004) Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood 103:2925\u20132928","journal-title":"Blood"},{"issue":"Suppl. II","key":"471_CR12","first-page":"202","volume":"66","author":"M Blom","year":"2007","unstructured":"Blom M, van den Hoogen FH, Voermans NC, van Riel PL, Preijers FW, van Engelen BG et al (2007) Successful treatment with rituximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 66(Suppl. II):202 [Abstract No. THU0245]","journal-title":"Ann Rheum Dis"},{"key":"471_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/ajh.20276","volume":"78","author":"P Braendstrup","year":"2005","unstructured":"Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB et al (2005) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 78:275\u2013280","journal-title":"Am J Hematol"},{"key":"471_CR14","first-page":"S23","volume":"25","author":"B Brihaye","year":"2007","unstructured":"Brihaye B, Aouba A, Pagnoux C, Cohen P, Lacassin F, Guillevin L (2007) Adjunction of rituximab to steroids and immunosuppressants for refractory\/relapsing Wegener\u2019s granulomatosis: a study on 8 patients. Clin Exp Rheumatol 25:S23\u2013S27","journal-title":"Clin Exp Rheumatol"},{"key":"471_CR15","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3816\/CLM.2006.n.052","volume":"7","author":"AH Bryce","year":"2006","unstructured":"Bryce AH, Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Inwards DJ et al (2006) Response to rituximab in patients with type II cryoglobulinemia. Clin Lymphoma Myeloma 7:140\u2013144","journal-title":"Clin Lymphoma Myeloma"},{"key":"471_CR16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/01.rhu.0000182155.08982.60","volume":"11","author":"N Chiappetta","year":"2005","unstructured":"Chiappetta N, Steier J, Gruber B (2005) Rituximab in the treatment of refractory dermatomyositis. J Clin Rheum 11:264\u2013266","journal-title":"J Clin Rheum"},{"key":"471_CR17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1445-5994.2007.01338.x","volume":"37","author":"KV Chow","year":"2007","unstructured":"Chow KV, Carroll R, Branley P, Nicholls K, Becker G, Hogan C (2007) Anti-CD20 antibody in thrombotic thrombocytopenic purpura refractory to plasma exchange. Intern Med J 37:329\u2013332","journal-title":"Intern Med J"},{"key":"471_CR18","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/j.1365-2141.2006.06311.x","volume":"135","author":"F Chowdhury","year":"2006","unstructured":"Chowdhury F, Lawrence K, Baglin T, Perry D (2006) Rituximab failure in a patient with allo-FVIII inhibitor. Br J Haematol 135:412","journal-title":"Br J Haematol"},{"key":"471_CR19","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1097\/01.bor.0000141925.21941.d8","volume":"16","author":"L Christopher-Stine","year":"2004","unstructured":"Christopher-Stine L, Plotz PH (2004) Myositis: an update on pathogenesis. Curr Opin Rheumatol 16:700\u2013706","journal-title":"Curr Opin Rheumatol"},{"key":"471_CR20","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1046\/j.1365-2249.2003.02111.x","volume":"132","author":"AR Clayton","year":"2003","unstructured":"Clayton AR, Savage CO (2003) Production of antineutrophil cytoplasm antibodies derived from circulating B cells in patients with systemic vasculitis. Clin Exp Immunol 132:174\u2013179","journal-title":"Clin Exp Immunol"},{"key":"471_CR21","first-page":"72","volume":"7","author":"SB Cohen","year":"2005","unstructured":"Cohen SB (2005) B-cell depletion for rheumatic diseases: where are we? MedGenMed 7:72","journal-title":"MedGenMed"},{"key":"471_CR22","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1365-2141.2004.04889.x","volume":"125","author":"N Cooper","year":"2004","unstructured":"Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S et al (2004) The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 125:232\u2013239","journal-title":"Br J Haematol"},{"key":"471_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jneuroim.2006.06.029","volume":"180","author":"AH Cross","year":"2006","unstructured":"Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA (2006) Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 180:63\u201370","journal-title":"J Neuroimmunol"},{"issue":"Suppl. II","key":"471_CR24","first-page":"70","volume":"66","author":"S Dass","year":"2007","unstructured":"Dass S, Bowman S, Vital EM, Ikeda K, Pease CT, Emery P (2007) Safety and efficacy of rituximab in Sj\u00f6gren\u2019s syndrome: results of a randomised, placebo-controlled trial. Ann Rheum Dis 66(Suppl. II):70 [Abstract No. OP0061]","journal-title":"Ann Rheum Dis"},{"key":"471_CR25","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.autrev.2006.02.007","volume":"5","author":"S de Vita","year":"2006","unstructured":"de Vita S, Quartuccio L (2006) Treatment of rheumatoid arthritis with rituximab: an update and possible indications. Autoimmun Rev 5:443\u2013448","journal-title":"Autoimmun Rev"},{"key":"471_CR26","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/art.22536","volume":"57","author":"V Devauchelle-Pensec","year":"2007","unstructured":"Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S et al (2007) Improvement of Sjogren\u2019s syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 57:310\u2013317","journal-title":"Arthritis Rheum"},{"key":"471_CR27","first-page":"464","volume":"7","author":"C Ding","year":"2006","unstructured":"Ding C, Jones G (2006) Belimumab (Human Genome Sciences\/Cambridge Antibody Technology\/GlaxoSmithKline). Curr Opin Investig Drugs 7:464\u2013472","journal-title":"Curr Opin Investig Drugs"},{"key":"471_CR28","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jaad.2006.05.068","volume":"56","author":"HV Dinh","year":"2007","unstructured":"Dinh HV, McCormack C, Hall S, Prince HM (2007) Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol 56:148\u2013153","journal-title":"J Am Acad Dermatol"},{"key":"471_CR29","doi-asserted-by":"publisher","first-page":"R74","DOI":"10.1186\/ar1942","volume":"8","author":"T Dorner","year":"2006","unstructured":"Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR (2006) Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 8:R74","journal-title":"Arthritis Res Ther"},{"key":"471_CR30","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","volume":"40","author":"JC Edwards","year":"2001","unstructured":"Edwards JC, Cambridge G (2001) Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 40:205\u2013211","journal-title":"Rheumatology (Oxford)"},{"key":"471_CR31","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/nri1838","volume":"6","author":"JC Edwards","year":"2006","unstructured":"Edwards JC, Cambridge G (2006) B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 6:394\u2013403","journal-title":"Nat Rev Immunol"},{"key":"471_CR32","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1136\/ard.2005.042143","volume":"65","author":"P Efthimiou","year":"2006","unstructured":"Efthimiou P, Paik PK, Bielory L (2006) Diagnosis and management of adult onset Still\u2019s disease. Ann Rheum Dis 65:564\u2013572","journal-title":"Ann Rheum Dis"},{"key":"471_CR33","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/ncprheum0042","volume":"2","author":"R Eisenberg","year":"2006","unstructured":"Eisenberg R, Albert D (2006) B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol 2:20\u201327","journal-title":"Nat Clin Pract Rheumatol"},{"key":"471_CR34","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1365-2796.2005.01494.x","volume":"257","author":"P Eriksson","year":"2005","unstructured":"Eriksson P (2005) Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 257:540\u2013548","journal-title":"J Intern Med"},{"key":"471_CR35","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1182\/blood-2005-03-0848","volume":"106","author":"F Fakhouri","year":"2005","unstructured":"Fakhouri F, Vernant JP, Veyradier A, Wolf M, Kaplanski G, Binaut R et al (2005) Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 106:1932\u20131937","journal-title":"Blood"},{"key":"471_CR36","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1600-0404.2005.00448.x","volume":"112","author":"J Finsterer","year":"2005","unstructured":"Finsterer J (2005) Treatment of immune-mediated, dysimmune neuropathies. Acta Neurol Scand 112:115\u2013125","journal-title":"Acta Neurol Scand"},{"key":"471_CR37","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0140-6736(05)66990-5","volume":"366","author":"RI Fox","year":"2005","unstructured":"Fox RI (2005) Sjogren\u2019s syndrome. Lancet 366:321\u2013331","journal-title":"Lancet"},{"key":"471_CR38","unstructured":"Fox RI (2007) FDA alert for rituximab in patients with systemic lupus erythematosus. Medscape Rheumatol"},{"key":"471_CR39","first-page":"11","volume":"52","author":"M Franchini","year":"2006","unstructured":"Franchini M (2006) The antiphospholipid syndrome: an update. Clin Lab 52:11\u201317","journal-title":"Clin Lab"},{"key":"471_CR40","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/art.22629","volume":"57","author":"JZ Gillis","year":"2007","unstructured":"Gillis JZ, Dall\u2019Era M, Gross A, Yazdany J, Davis J (2007) Six refractory lupus patients treated with rituximab: a case series. Arthritis Rheum 57:538\u2013542","journal-title":"Arthritis Rheum"},{"key":"471_CR41","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S1074-7613(01)00183-2","volume":"15","author":"JA Gross","year":"2001","unstructured":"Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R et al (2001) TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity 15:289\u2013302","journal-title":"Immunity"},{"key":"471_CR42","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/art.22505","volume":"56","author":"I Gunnarsson","year":"2007","unstructured":"Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF (2007) Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 56:1263\u20131272","journal-title":"Arthritis Rheum"},{"key":"471_CR43","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/01.bor.0000172801.56744.c3","volume":"17","author":"A Hansen","year":"2005","unstructured":"Hansen A, Lipsky PE, D\u00f6rner T (2005) Immunopathogenesis of primary Sj\u00f6gren\u2019s syndrome: implications for disease management and therapy. Curr Opin Rheumatol 17:558\u2013565","journal-title":"Curr Opin Rheumatol"},{"key":"471_CR44","unstructured":"Hauser S, Waubant E, Arnold D, Vollmer T, Antel J, Fox R et al (2007) A Phase II randomized, placebo-controlled, multicenter trial of rituximab in adults with relapsing remitting multiple sclerosis (RRMS). In: American Academy of Neurology 59th annual meeting, Boston, April 28\u2013May 5, 2007 [Abstract No. S.12.003]"},{"key":"471_CR45","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1160\/TH06-09-0499","volume":"97","author":"F Heidel","year":"2007","unstructured":"Heidel F, Lipka DB, von Auer C, Huber C, Scharrer I, Hess G (2007) Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thromb Haemost 97:228\u2013233","journal-title":"Thromb Haemost"},{"key":"471_CR46","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1136\/pmj.78.924.599","volume":"78","author":"Y Ioannou","year":"2002","unstructured":"Ioannou Y, Isenberg DA (2002) Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge. Postgrad Med J 78:599\u2013606","journal-title":"Postgrad Med J"},{"key":"471_CR47","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.berh.2004.05.004","volume":"18","author":"J Kadar","year":"2004","unstructured":"Kadar J, Petrovicz E (2004) Adult-onset Still\u2019s disease. Best Pract Res Clin Rheumatol 18:663\u2013676","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"471_CR48","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.smim.2006.06.002","volume":"18","author":"SL Kalled","year":"2006","unstructured":"Kalled SL (2006) Impact of the BAFF\/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin Immunol 18:290\u2013296","journal-title":"Semin Immunol"},{"key":"471_CR49","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1136\/ard.2005.047308","volume":"65","author":"VV Kaushik","year":"2006","unstructured":"Kaushik VV, Reddy HV, Bucknall RC (2006) Successful use of rituximab in a patient with recalcitrant Churg\u2013Strauss syndrome. Ann Rheum Dis 65:1116\u20131117","journal-title":"Ann Rheum Dis"},{"key":"471_CR50","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/art.20718","volume":"52","author":"KA Keogh","year":"2005","unstructured":"Keogh KA, Wylam ME, Stone JH, Specks U (2005) Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52:262\u2013268","journal-title":"Arthritis Rheum"},{"key":"471_CR51","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1164\/rccm.200507-1144OC","volume":"173","author":"KA Keogh","year":"2006","unstructured":"Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U (2006) Rituximab for refractory Wegener\u2019s granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 173:180\u2013187","journal-title":"Am J Respir Crit Care Med"},{"key":"471_CR52","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/ard.2005.042937","volume":"65","author":"M Koukoulaki","year":"2006","unstructured":"Koukoulaki M, Smith KG, Jayne DR (2006) Rituximab in Churg\u2013Strauss syndrome. Ann Rheum Dis 65:557\u2013559","journal-title":"Ann Rheum Dis"},{"key":"471_CR53","first-page":"1369","volume":"32","author":"O Lambotte","year":"2005","unstructured":"Lambotte O, Kotb R, Maigne G, Blanc FX, Goujard C, Delfraissy JF (2005) Efficacy of rituximab in refractory polymyositis. J Rheumatol 32:1369\u20131370","journal-title":"J Rheumatol"},{"key":"471_CR54","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/ar771","volume":"5","author":"CA Langford","year":"2003","unstructured":"Langford CA (2003) Wegener\u2019s granulomatosis: current and upcoming therapies. Arthritis Res Ther 5:180\u2013191","journal-title":"Arthritis Res Ther"},{"key":"471_CR55","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1093\/rheumatology\/kei080","volume":"44","author":"MJ Leandro","year":"2005","unstructured":"Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA (2005) B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 44:1542\u20131545","journal-title":"Rheumatology (Oxford)"},{"key":"471_CR56","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/art.20849","volume":"52","author":"TD Levine","year":"2005","unstructured":"Levine TD (2005) Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52:601\u2013607","journal-title":"Arthritis Rheum"},{"key":"471_CR57","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/ni0901-764","volume":"2","author":"PE Lipsky","year":"2001","unstructured":"Lipsky PE (2001) Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2:764\u2013766","journal-title":"Nat Immunol"},{"key":"471_CR58","doi-asserted-by":"publisher","first-page":"625","DOI":"10.2165\/00003495-200666050-00004","volume":"66","author":"RJ Looney","year":"2006","unstructured":"Looney RJ (2006) B cell-targeted therapy for rheumatoid arthritis: an update on the evidence. Drugs 66:625\u2013639","journal-title":"Drugs"},{"key":"471_CR59","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/art.20430","volume":"50","author":"RJ Looney","year":"2004","unstructured":"Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ et al (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab. Arthritis Rheum 50:2580\u20132589","journal-title":"Arthritis Rheum"},{"key":"471_CR60","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-L\u00f3pez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA et al (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood 90:2188\u20132195","journal-title":"Blood"},{"key":"471_CR61","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/ajh.20180","volume":"77","author":"E Mantadakis","year":"2004","unstructured":"Mantadakis E, Danilatou V, Stiakaki E, Kalmanti M (2004) Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases. Am J Hematol 77:303\u2013310","journal-title":"Am J Hematol"},{"issue":"Suppl II","key":"471_CR62","first-page":"216","volume":"66","author":"CC Mok","year":"2007","unstructured":"Mok CC, Ho LY, To CH (2007) Rituximab for refractory polymyositis: an open-label pilot study. Ann Rheum Dis 66(Suppl II):216 [Abstract No. THU0292]","journal-title":"Ann Rheum Dis"},{"key":"471_CR63","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/archneur.62.2.258","volume":"62","author":"NL Monson","year":"2005","unstructured":"Monson NL, Cravens PD, Frohman EM, Hawker K, Racke MK (2005) Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 62:258\u2013264","journal-title":"Arch Neurol"},{"issue":"Suppl. II","key":"471_CR64","first-page":"56","volume":"66","author":"KP Ng","year":"2007","unstructured":"Ng KP, Cambridge G, Leandro M, Edwards JC, Ehrenstein MR, Isenberg DA (2007) B cell depletion therapy in patients with systemic lupus erythematosus: long term follow up and predictors of response. Ann Rheum Dis 66(Suppl. II):56 [Abstract No. OP0020]","journal-title":"Ann Rheum Dis"},{"key":"471_CR65","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1365-2141.2005.05809.x","volume":"132","author":"A Norton","year":"2006","unstructured":"Norton A, Roberts I (2006) Management of Evans syndrome. Br J Haematol 132:125\u2013137","journal-title":"Br J Haematol"},{"key":"471_CR66","first-page":"1021","volume":"33","author":"EH Noss","year":"2006","unstructured":"Noss EH, Hausner-Sypek DL, Weinblatt ME (2006) Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 33:1021\u20131026","journal-title":"J Rheumatol"},{"key":"471_CR67","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/01.rhu.0000260656.05638.f7","volume":"13","author":"B Oliveira","year":"2007","unstructured":"Oliveira B, Arkfeld DG, Weitz IC, Shinada S, Ehresmann G (2007) Successful rituximab therapy of acquired factor VIII inhibitor in a patient with rheumatoid arthritis. J Clin Rheumatol 13:89\u201391","journal-title":"J Clin Rheumatol"},{"key":"471_CR68","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/02813430510015269","volume":"34","author":"R Omdal","year":"2005","unstructured":"Omdal R, Wildhagen K, Hansen T, Gunnarsson R, Kristoffersen G (2005) Anti-CD20 therapy of treatment-resistant Wegener\u2019s granulomatosis: favourable but temporary response. Scand J Rheumatol 34:229\u2013232","journal-title":"Scand J Rheumatol"},{"key":"471_CR69","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11239-006-9051-2","volume":"23","author":"H Ozdogu","year":"2007","unstructured":"Ozdogu H, Boga C, Kizilkilic E, Yeral M, Kozanoglu I, Karatas M (2007) A dramatic response to rituximab in a patient with resistant thrombotic thrombocytopenic purpura (TTP) who developed acute stroke. J Thromb Thrombolysis 23:147\u2013150","journal-title":"J Thromb Thrombolysis"},{"key":"471_CR70","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/jca.20113","volume":"22","author":"W Patino","year":"2007","unstructured":"Patino W, Sarode R (2007) Successful repeat therapy with rituximab for relapsed thrombotic thrombocytopenic purpura. J Clin Apher 22:17\u201320","journal-title":"J Clin Apher"},{"key":"471_CR71","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s00277-006-0123-3","volume":"85","author":"FJ Penalver","year":"2006","unstructured":"Penalver FJ, Jimenez-Yuste V, Almagro M, Alvarez-Larran A, Rodriguez L, Casado M et al (2006) Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol 85:400\u2013406","journal-title":"Ann Hematol"},{"key":"471_CR72","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/107602960601200116","volume":"12","author":"AL Perrotta","year":"2006","unstructured":"Perrotta AL (2006) Re-treatment of chronic idiopathic thrombocytopenic purpura with rituximab: literature review. Clin Appl Thromb Hemost 12:97\u2013100","journal-title":"Clin Appl Thromb Hemost"},{"key":"471_CR73","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1002\/art.21260","volume":"52","author":"J Pijpe","year":"2005","unstructured":"Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K et al (2005) Rituximab treatment in patients with primary Sjogren\u2019s syndrome: an open-label phase II study. Arthritis Rheum 52:2740\u20132750","journal-title":"Arthritis Rheum"},{"key":"471_CR74","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s00277-004-0964-6","volume":"84","author":"PS Reddy","year":"2005","unstructured":"Reddy PS, Deauna-Limayo D, Cook JD, Ganguly SS, Blecke C, Bodensteiner DC et al (2005) Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Ann Hematol 84:232\u2013235","journal-title":"Ann Hematol"},{"key":"471_CR75","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1182\/blood-2004-11-4490","volume":"106","author":"M Rieger","year":"2005","unstructured":"Rieger M, Mannucci PM, Kremer Hovinga JA, Herzog A, Gerstenbauer G, Konetschny C et al (2005) ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 106:1262\u20131267","journal-title":"Blood"},{"key":"471_CR76","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s10067-005-0086-0","volume":"25","author":"T Ring","year":"2006","unstructured":"Ring T, Kallenbach M, Praetorius J, Nielsen S, Melgaard B (2006) Successful treatment of a patient with primary Sjogren\u2019s syndrome with Rituximab. Clin Rheumatol 25:891\u2013894","journal-title":"Clin Rheumatol"},{"key":"471_CR77","first-page":"355","volume":"33","author":"E Rubenstein","year":"2006","unstructured":"Rubenstein E, Arkfeld DG, Metyas S, Shinada S, Ehresmann S, Liebman HA (2006) Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol 33:355\u2013357","journal-title":"J Rheumatol"},{"key":"471_CR78","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.2165\/00003495-200666150-00004","volume":"66","author":"R Sabahi","year":"2006","unstructured":"Sabahi R, Anolik JH (2006) B-cell-targeted therapy for systemic lupus erythematosus. Drugs 66:1933\u20131948","journal-title":"Drugs"},{"key":"471_CR79","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1093\/ndt\/gfl796","volume":"22","author":"D S\u00e1nchez-Cano","year":"2007","unstructured":"S\u00e1nchez-Cano D, Callejas-Rubio JL, Rios-Fern\u00e1ndez R, Ortego-Centeno N (2007) Use of rituximab in Wegener\u2019s granulomatosis: comment on the article by Wong. Nephrol Dial Transplant 22:958\u2013959","journal-title":"Nephrol Dial Transplant"},{"key":"471_CR80","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1182\/blood-2002-10-3162","volume":"101","author":"D Sansonno","year":"2003","unstructured":"Sansonno D, de Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F (2003) Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101:3818\u20133826","journal-title":"Blood"},{"key":"471_CR81","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/10428190500286481","volume":"47","author":"C Schollkopf","year":"2006","unstructured":"Schollkopf C, Kjeldsen L, Bjerrum OW, Mourits-Andersen HT, Nielsen JL, Christensen BE et al (2006) Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma 47:253\u2013260","journal-title":"Leuk Lymphoma"},{"key":"471_CR82","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1365-2141.2006.06448.x","volume":"136","author":"M Scully","year":"2007","unstructured":"Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S et al (2007) Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 136:451\u2013461","journal-title":"Br J Haematol"},{"key":"471_CR83","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/ard.2006.057919","volume":"66","author":"R Seror","year":"2007","unstructured":"Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M et al (2007) Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren\u2019s syndrome. Ann Rheum Dis 66:351\u2013357","journal-title":"Ann Rheum Dis"},{"key":"471_CR84","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/art.20858","volume":"52","author":"PP Sfikakis","year":"2005","unstructured":"Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A et al (2005) Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 52:501\u2013513","journal-title":"Arthritis Rheum"},{"key":"471_CR85","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1002\/art.22046","volume":"54","author":"KG Smith","year":"2006","unstructured":"Smith KG, Jones RB, Burns SM, Jayne DR (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 54:2970\u20132982","journal-title":"Arthritis Rheum"},{"key":"471_CR86","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3324\/haematol.10553","volume":"92","author":"WR Sperr","year":"2007","unstructured":"Sperr WR, Lechner K, Pabinger I (2007) Rituximab for the treatment of acquired antibodies to factor VIII. Haematologica 92:66\u201371","journal-title":"Haematologica"},{"key":"471_CR87","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1182\/blood.V98.4.952","volume":"98","author":"R Stasi","year":"2001","unstructured":"Stasi R, Pagano A, Stipa E, Amadori S (2001) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98:952\u2013957","journal-title":"Blood"},{"key":"471_CR88","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1093\/rheumatology\/kel098","volume":"45","author":"R Stasi","year":"2006","unstructured":"Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D (2006) Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 45:1432\u20131436","journal-title":"Rheumatology (Oxford)"},{"key":"471_CR89","doi-asserted-by":"publisher","first-page":"R129","DOI":"10.1186\/ar2018","volume":"8","author":"SD Steinfeld","year":"2006","unstructured":"Steinfeld SD, Tant L, Burmester GR, Teoh NK, Wegener WA, Goldenberg DM et al (2006) Epratuzumab (humanised anti-CD22 antibody) in primary Sj\u00f6gren\u2019s syndrome: an open-label phase I\/II study. Arthritis Res Ther 8:R129","journal-title":"Arthritis Res Ther"},{"key":"471_CR90","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1517\/14712598.6.9.943","volume":"6","author":"SD Steinfeld","year":"2006","unstructured":"Steinfeld SD, Youinou P (2006) Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases. Expert Opin Biol Ther 6:943\u2013949","journal-title":"Expert Opin Biol Ther"},{"key":"471_CR91","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2169\/internalmedicine.46.6156","volume":"46","author":"N Tamura","year":"2007","unstructured":"Tamura N, Matsudaira R, Hirashima M, Ikeda M, Tajima M, Nawata M et al (2007) Two cases of refractory Wegener\u2019s granulomatosis successfully treated with rituximab. Intern Med 46:409\u2013414","journal-title":"Intern Med"},{"key":"471_CR92","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1136\/ard.2006.057885","volume":"66","author":"M Tokunaga","year":"2007","unstructured":"Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S et al (2007) Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 66:470\u2013475","journal-title":"Ann Rheum Dis"},{"key":"471_CR93","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/03009740500484056","volume":"35","author":"Z Touma","year":"2006","unstructured":"Touma Z, Sayad J, Arayssi T (2006) Successful treatment of Sjogren\u2019s syndrome with rituximab. Scand J Rheumatol 35:323\u2013325","journal-title":"Scand J Rheumatol"},{"key":"471_CR94","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s00277-005-0028-6","volume":"85","author":"R Trappe","year":"2006","unstructured":"Trappe R, Loew A, Thuss-Patience P, Dorken B, Riess H (2006) Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab-monitoring of antiphospholipid and anti-GP antibodies: a case report. Ann Hematol 85:134\u2013135","journal-title":"Ann Hematol"},{"key":"471_CR95","doi-asserted-by":"publisher","first-page":"R83","DOI":"10.1186\/ar1954","volume":"8","author":"M Vigna-Perez","year":"2006","unstructured":"Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, Portales-Perez D, Baranda L, Abud-Mendoza C et al (2006) Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 8:R83","journal-title":"Arthritis Res Ther"},{"key":"471_CR96","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","volume":"21","author":"WK Weng","year":"2003","unstructured":"Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940\u20133947","journal-title":"J Clin Oncol"},{"key":"471_CR97","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/ar758","volume":"5","author":"A Wiik","year":"2003","unstructured":"Wiik A (2003) Autoantibodies in vasculitis. Arthritis Res Ther 5:147\u2013152","journal-title":"Arthritis Res Ther"},{"key":"471_CR98","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/ndt\/gfl573","volume":"22","author":"CF Wong","year":"2007","unstructured":"Wong CF (2007) Rituximab in refractory antineutrophil cytoplasmic antibody-associated vasculitis: what is the current evidence? Nephrol Dial Transplant 22:32\u201336","journal-title":"Nephrol Dial Transplant"},{"key":"471_CR99","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/j.1365-2141.2004.04836.x","volume":"124","author":"R Yomtovian","year":"2004","unstructured":"Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai HM (2004) Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 124:787\u2013795","journal-title":"Br J Haematol"},{"key":"471_CR100","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.thromres.2004.06.019","volume":"114","author":"P Youinou","year":"2004","unstructured":"Youinou P, Renaudineau Y (2004) The antiphospholipid syndrome as a model for B cell-induced autoimmune diseases. Thromb Res 114:363\u2013369","journal-title":"Thromb Res"},{"key":"471_CR101","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1182\/blood-2002-09-2856","volume":"101","author":"F Zaja","year":"2003","unstructured":"Zaja F, de Vita S, Mazzaro C, Sacco S, Damiani D, de Marchi G et al (2003) Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101:3827\u20133834","journal-title":"Blood"},{"key":"471_CR102","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.exphem.2006.02.009","volume":"34","author":"F Zaja","year":"2006","unstructured":"Zaja F, Vianelli N, Battista M, Sperotto A, Patriarca F, Tomadini V et al (2006) Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. Exp Hematol 34:571\u2013572","journal-title":"Exp Hematol"},{"key":"471_CR103","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0889-857X(05)70205-2","volume":"27","author":"Z Zhang","year":"2001","unstructured":"Zhang Z, Bridges SL Jr (2001) Pathogenesis of rheumatoid arthritis. Role of B lymphocytes. Rheum Dis Clin North Am 27:335\u2013353","journal-title":"Rheum Dis Clin North Am"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-007-0471-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-007-0471-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-007-0471-x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-007-0471-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T19:32:53Z","timestamp":1630438373000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-007-0471-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,24]]},"references-count":104,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["471"],"URL":"https:\/\/doi.org\/10.1007\/s00296-007-0471-x","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,24]]},"assertion":[{"value":"13 August 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}